S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
Log in

NASDAQ:PETQPetIQ Stock Price, Forecast & News

$31.53
-5.96 (-15.90 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$30.85
Now: $31.53▼
$37.05
50-Day Range
$31.68
MA: $35.05▼
$37.49
52-Week Range
$15.83
Now: $31.53▼
$38.99
Volume1.80 million shs
Average Volume395,877 shs
Market Capitalization$894.82 million
P/E RatioN/A
Dividend YieldN/A
Beta1.66
PetIQ, Inc. operates as a pet health and wellness company. It operates through two segments, Products and Services. It manufactures and distributes veterinarian services and veterinarian-grade pet products, including prescription (Rx) medications, over-the-counter (OTC) flea and tick preventatives, and health and wellness products for dogs and cats. The company offers Rx pet medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; and OTC medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars. It also provides health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company offers its products primarily under the PetIQ, PetAction Plus, Advecta, PetLock Plus, and TruProfen brands. In addition, the company offers a suite of services at community clinics and wellness centers hosted at pet retailers across 39 states, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. It sells its products through approximately 60,000 points of distribution across retail and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.
Read More
PetIQ logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.78 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Drugs, proprietaries, & sundries
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PETQ
Previous Symbol
CUSIPN/A
CIK1668673
Webwww.petiq.com
Phone208-939-8900

Debt

Debt-to-Equity Ratio1.04
Current Ratio2.85
Quick Ratio1.67

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio29.75
P/E Growth1.39

Sales & Book Value

Annual Sales$709.43 million
Price / Sales1.26
Cash Flow$1.22 per share
Price / Cash Flow25.74
Book Value$11.60 per share
Price / Book2.72

Profitability

EPS (Most Recent Fiscal Year)$1.07
Net Income$-11,450,000.00
Net Margins-2.03%
Return on Equity8.28%
Return on Assets4.15%

Miscellaneous

Employees1,866
Outstanding Shares28,380,000
Market Cap$894.82 million
Next Earnings DateN/A
OptionableOptionable
$31.53
-5.96 (-15.90 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PETQ News and Ratings via Email

Sign-up to receive the latest news and ratings for PETQ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











PetIQ (NASDAQ:PETQ) Frequently Asked Questions

How has PetIQ's stock been impacted by COVID-19 (Coronavirus)?

PetIQ's stock was trading at $22.59 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PETQ stock has increased by 39.6% and is now trading at $31.53.
View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of PetIQ?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PetIQ in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for PetIQ.

How were PetIQ's earnings last quarter?

PetIQ Inc (NASDAQ:PETQ) issued its earnings results on Tuesday, March, 10th. The company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.09 by $0.18. The company had revenue of $154.34 million for the quarter, compared to the consensus estimate of $134.80 million. PetIQ had a positive return on equity of 8.28% and a negative net margin of 2.03%.
View PetIQ's earnings history.

What guidance has PetIQ issued on next quarter's earnings?

PetIQ updated its third quarter 2020 After-Hours earnings guidance on Thursday, August, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $160-170 million, compared to the consensus revenue estimate of $205.77 million.

What price target have analysts set for PETQ?

4 brokers have issued twelve-month target prices for PetIQ's stock. Their forecasts range from $44.00 to $50.00. On average, they expect PetIQ's stock price to reach $45.75 in the next twelve months. This suggests a possible upside of 45.1% from the stock's current price.
View analysts' price targets for PetIQ.

Has PetIQ been receiving favorable news coverage?

News headlines about PETQ stock have trended very positive this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. PetIQ earned a coverage optimism score of 4.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about PetIQ.

Who are some of PetIQ's key competitors?

Some companies that are related to PetIQ include McKesson (MCK), AmerisourceBergen (ABC), Cardinal Health (CAH), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), Trxade Group (TRXD), MultiCell Technologies (MEDS) and biOasis Technologies (BIOAF).
View all competitors.

What other stocks do shareholders of PetIQ own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PetIQ investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Intel (INTC), Advanced Micro Devices (AMD), CVS Health (CVS), Exelixis (EXEL), salesforce.com (CRM), Crispr Therapeutics (CRSP) and IBM (IBM).

Who are PetIQ's key executives?

PetIQ's management team includes the following people:
  • Mr. McCord Christensen, Chairman & CEO (Age 47)
  • Ms. Susan Sholtis, Pres (Age 53)
  • Mr. John Newland, Chief Financial Officer (Age 55)
  • Mr. Robert Michael Herrman, Gen. Counsel & Sec.
  • Mr. Adam Fellers, Sr. VP of Sales

When did PetIQ IPO?

(PETQ) raised $86 million in an IPO on Friday, July 21st 2017. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. Jefferies and William Blair acted as the underwriters for the IPO and Oppenheimer, Raymond James and SunTrust Robinson Humphrey were co-managers.

What is PetIQ's stock symbol?

PetIQ trades on the NASDAQ under the ticker symbol "PETQ."

Who are PetIQ's major shareholders?

PetIQ's stock is owned by a variety of retail and institutional investors. Top institutional investors include Riverbridge Partners LLC (2.36%), Peregrine Capital Management LLC (2.16%), Russell Investments Group Ltd. (1.27%), AMI Asset Management Corp (0.98%), Nepsis Inc. (0.79%) and Aperture Investors LLC (0.67%). Company insiders that own PetIQ stock include Ecp Helios Partners Iv, LP, James Nathan Clarke, John Newland, Mccord Christensen, Robert Michael Herrman, Susan Sholtis and Will Santana.
View institutional ownership trends for PetIQ.

Which major investors are selling PetIQ stock?

PETQ stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Peregrine Capital Management LLC, Aperture Investors LLC, WINTON GROUP Ltd, PNC Financial Services Group Inc., AMI Asset Management Corp, Principal Financial Group Inc., and Nepsis Inc..
View insider buying and selling activity for PetIQ.

Which major investors are buying PetIQ stock?

PETQ stock was bought by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Cadence Capital Management LLC, TRH Financial LLC, UBS Group AG, Toth Financial Advisory Corp, Keeler Thomas Management LLC, SG Americas Securities LLC, and Envestnet Asset Management Inc.. Company insiders that have bought PetIQ stock in the last two years include James Nathan Clarke, John Newland, and Robert Michael Herrman.
View insider buying and selling activity for PetIQ.

How do I buy shares of PetIQ?

Shares of PETQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PetIQ's stock price today?

One share of PETQ stock can currently be purchased for approximately $31.53.

How big of a company is PetIQ?

PetIQ has a market capitalization of $894.82 million and generates $709.43 million in revenue each year. The company earns $-11,450,000.00 in net income (profit) each year or $1.07 on an earnings per share basis. PetIQ employs 1,866 workers across the globe.

What is PetIQ's official website?

The official website for PetIQ is www.petiq.com.

How can I contact PetIQ?

PetIQ's mailing address is 923 S. Bridgeway Pl., EAGLE ID, 83616. The company can be reached via phone at 208-939-8900 or via email at [email protected]

This page was last updated on 8/7/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.